Your browser is no longer supported. Please, upgrade your browser.
Settings
INCY Incyte Corporation daily Stock Chart
INCY [NASD]
Incyte Corporation
IndexS&P 500 P/E- EPS (ttm)-0.79 Insider Own0.30% Shs Outstand211.68M Perf Week4.10%
Market Cap15.54B Forward P/E34.64 EPS next Y2.12 Insider Trans-11.27% Shs Float211.18M Perf Month9.94%
Income-167.20M PEG- EPS next Q0.28 Inst Own96.80% Short Float2.84% Perf Quarter-17.30%
Sales1.53B P/S10.13 EPS this Y-385.10% Inst Trans-0.51% Short Ratio2.28 Perf Half Y-21.52%
Book/sh7.69 P/B9.55 EPS next Y89.45% ROA-7.80% Target Price81.29 Perf Year-41.06%
Cash/sh5.53 P/C13.27 EPS next 5Y31.09% ROE-11.10% 52W Range60.22 - 140.11 Perf YTD-22.47%
Dividend- P/FCF785.04 EPS past 5Y-35.00% ROI-14.80% 52W High-47.59% Beta0.71
Dividend %- Quick Ratio3.80 Sales past 5Y38.90% Gross Margin95.00% 52W Low21.93% ATR2.08
Employees1208 Current Ratio3.90 Sales Q/Q-0.50% Oper. Margin-11.60% RSI (14)65.62 Volatility3.46% 2.83%
OptionableYes Debt/Eq0.01 EPS Q/Q79.70% Profit Margin-10.90% Rel Volume0.68 Prev Close72.98
ShortableYes LT Debt/Eq0.01 EarningsJul 31 BMO Payout- Avg Volume2.63M Price73.43
Recom2.10 SMA205.93% SMA509.23% SMA200-19.85% Volume1,785,487 Change0.62%
Jun-11-18Upgrade Evercore ISI In-line → Outperform
Apr-09-18Reiterated Credit Suisse Outperform $145 → $78
Apr-09-18Downgrade Gabelli & Co Buy → Hold
Apr-06-18Downgrade William Blair Outperform → Mkt Perform
Apr-06-18Downgrade Guggenheim Buy → Neutral
Apr-05-18Reiterated Barclays Overweight $165 → $135
Jan-02-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Nov-21-17Reiterated RBC Capital Mkts Sector Perform $136 → $120
Oct-06-17Resumed Goldman Buy $160
Sep-15-17Initiated RBC Capital Mkts Sector Perform $136
Sep-11-17Upgrade Raymond James Mkt Perform → Outperform
Aug-17-17Initiated Evercore ISI In-line $135
May-12-17Initiated Oppenheimer Perform
Apr-17-17Downgrade Piper Jaffray Overweight → Neutral
Apr-10-17Initiated Gabelli & Co Buy $185
Apr-07-17Reiterated Barclays Overweight $135 → $185
Apr-05-17Downgrade Raymond James Outperform → Mkt Perform
Apr-04-17Reiterated RBC Capital Mkts Outperform $138 → $157
Mar-09-17Initiated UBS Neutral $140
Mar-02-17Initiated Instinet Buy $148
Jun-11-18 02:58PM  Former Incyte CEO Buys Slumping Nektar Shares Barrons.com
06:45AM  Lilly to Unveil New Data at the Annual European Congress of Rheumatology, Furthering Commitment to Scientific Discovery in Immunology PR Newswire
Jun-10-18 09:40AM  3 Reasons to Expect Smooth Sailing for AbbVie's Mission-Critical Candidate Motley Fool
Jun-08-18 09:37AM  Here's Why Incyte Rose 10.2% in May Motley Fool
Jun-05-18 06:02PM  Lifshitz & Miller LLP Announces Investigation of ARMO BioSciences, Inc., Financial Engines, Inc., Globalstar, Inc., Gridsum Holding Inc., InnerWorkings, Inc., Incyte Corporation, PPG Industries, Inc., and Spectrum Brands Holdings, Inc. PR Newswire
Jun-04-18 11:05AM  Eli Lilly's Olumiant Gets FDA Nod for Rheumatoid Arthritis Zacks
Jun-01-18 01:58PM  Lilly gets U.S. nod for arthritis drug, sets price well below rivals Reuters
12:04PM  FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis PR Newswire
08:16AM  Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO Benzinga
May-31-18 11:43AM  Incyte (INCY) Up 10.2% Since Earnings Report: Can It Continue? Zacks
06:31AM  3 Biotechs With Huge FDA Decisions in June Motley Fool
May-30-18 12:00AM  [$$] Drugmakers struggle to find immunotherapy combinations for cancer Financial Times
May-29-18 07:30AM  [$$] Gormley's Take: Searching for Better Cancer Drug Combinations The Wall Street Journal
May-26-18 11:07AM  The Week Ahead In Biotech: ASCO Presentations In The Spotlight Benzinga
May-24-18 08:00AM  Incyte to Present at Upcoming Investor Conferences Business Wire
07:33AM  Jim Cramer Gives His Opinion On Blue Apron, Teva And More Benzinga
May-23-18 07:02PM  Cramer's lightning round: I don't have a thesis for Blue ... CNBC Videos
May-12-18 09:28AM  Is Agenus Inc. (AGEN) a Buy? Motley Fool
May-10-18 05:50PM  Big Peninsula biotech buyout means happy returns for Kleiner Perkins, other VCs American City Business Journals
07:55AM  Detailed Research: Economic Perspectives on Voya Financial, Dominion Energy, Incyte, MeetMe, Ventas, and Select Medical What Drives Growth in Today's Competitive Landscape GlobeNewswire
May-08-18 12:56AM  Insider Buying Roundup: Elon Musk Buys Tesla (TSLA) Shares After Earnings Call Backlash Insider Monkey
May-07-18 03:59AM  Edited Transcript of INCY earnings conference call or presentation 1-May-18 12:00pm GMT Thomson Reuters StreetEvents
May-01-18 03:24PM  Incyte (INCY) Incurs Loss in Q1, Revenues Miss Estimates Zacks
10:13AM  Biotech: Better Luck Next Time Barrons.com
09:08AM  Incyte (INCY) Reports A Loss in Q1 Zacks
07:00AM  Incyte Reports 2018 First-Quarter Financial Results and Updates on Key Clinical Programs Business Wire
Apr-30-18 08:18PM  Edited Transcript of INCY earnings conference call or presentation 15-Feb-18 1:00pm GMT Thomson Reuters StreetEvents
10:11AM  Drug Stocks Q1 Earnings to Watch on May 1: PFE, MRK & More Zacks
09:20AM  Google's Alphabet Median Pay Close To $200K Investopedia
08:50AM  Should You Sell Incyte (INCY) Before Earnings? Zacks
Apr-27-18 09:48AM  Can Jafaki Help Incyte (INCY) Beat Earnings Estimates in Q1? Zacks
Apr-26-18 08:00AM  Incyte to Present at Upcoming Investor Conference Business Wire
Apr-25-18 05:38PM  Incyte Highlights Abstracts Accepted for Presentation at the 2018 ASCO Annual Meeting Business Wire
10:33AM  Lessons to Learn From April's Biotech Blowups Motley Fool
08:30AM  Today's Research Reports on Trending Tickers: Allergan and Incyte Corporation ACCESSWIRE
Apr-24-18 11:59AM  Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug TheStreet.com -8.50%
07:30AM  Eli Lilly, Incyte shares drop after mixed FDA drug recommendation MarketWatch
07:03AM  Eli Lilly's earnings beat expectations, and its improved outlook overcomes regulatory setback CNBC
Apr-23-18 08:10PM  FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis PR Newswire
06:44PM  FDA panel against higher dose of Lilly-Incyte arthritis drug Reuters
05:01PM  FDA panel votes against approving higher dose of Lilly-Incyte arthritis drug Reuters
Apr-20-18 10:54AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Incyte Corporation (INCY) PR Newswire
08:03AM  3 Biotech Stocks With Major Catalysts Incoming Motley Fool
Apr-19-18 05:27PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Incyte Corporation - INCY PR Newswire
02:09PM  Eli Lilly's Blockbuster Resurrection Story Has Holes Bloomberg
02:01PM  Gilead shares drop on FDA concerns with similar Eli Lilly, Incyte drug MarketWatch
09:10AM  Eli Lilly, Incyte shares fall after FDA cites issues with rheumatoid arthritis drug MarketWatch
08:15AM  FDA staff cites safety issues for Lilly, Incyte's rheumatoid arthritis drug Reuters
Apr-16-18 05:01PM  What Incyte's Phase 3 Fail Means for Immuno-Oncology Motley Fool
04:21PM  NewLink Shares Bite The Dust After Merck-Incyte Melanoma Failure Investor's Business Daily
04:16PM  What's Next for Incyte? Motley Fool
08:48AM  NewLink shares fall on late-stage trial changes MarketWatch
08:17AM  The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte Zacks
Apr-13-18 06:01PM  What Happened With Incyte's IDO Inhibitor Flop Motley Fool
09:33AM  Pharma M&A Active This Week: 4 Potential Buyout Targets Zacks
08:00AM  Incyte to Report First Quarter Financial Results Business Wire
Apr-12-18 06:00PM  Why One Drug Flop Tanked Incyte's Stock Motley Fool +5.34%
05:38PM  The Biggest Movers: Incyte Excites; L Brands Slides Barrons.com
04:37PM  Why GoPro, Incyte, and Wynn Resorts Jumped Today Motley Fool
11:48AM  3 Biotech Stocks Analysts Have Been Too Bullish On Investopedia
Apr-11-18 10:20AM  Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis Zacks
08:17AM  Is Beaten-Down Incyte Corporation Stock a Buy Now? Motley Fool
06:00AM  10 Cheap, High-Quality Stocks With Major Growth Catalysts Morningstar
Apr-10-18 02:05PM  MARKETS: Welcome to the low volume, low liquidity algo-driven market Yahoo Finance Video
Apr-09-18 05:24PM  NewLink Shares Plunge After Incyte & Merck's Study Fails Zacks
02:24PM  NewLink Genetics' Potential Catalysts Not Enough To Justify A Bullish Stance, Baird Says In Downgrade Benzinga
01:41PM  Incyte Cancer Drug Flop Is Costly and Likely to Be Duplicated Bloomberg
10:29AM  Cantor Fitzgerald Double Downgrades NewLink Genetics After Incyte's Disappointing Trial Benzinga
09:48AM  Incyte's Epacadostat Fails in Melanoma Study, Shares Plunge Zacks
08:10AM  Todays Research Reports on Stocks to Watch: Incyte and Merck ACCESSWIRE
Apr-08-18 11:54PM  [$$] Biotech Gets a Reality Check The Wall Street Journal
Apr-06-18 10:57PM  [$$] Incyte Shares Tumble After Cancer Drug Fails in Trial With Mercks Keytruda The Wall Street Journal -22.93%
06:30PM  Incyte's Horrible News Derails a Promising Class of Cancer Drugs Motley Fool
05:09PM  What Happened in the Stock Market Today Motley Fool
04:51PM  The Biggest Movers: Ventas Edges Up; Incyte Plunges Barrons.com
04:34PM  Synchrony, Incyte and Lockheed tumble Associated Press
04:29PM  [$$] Biotech Gets a Reality Check The Wall Street Journal
04:06PM  How Incyte's 'Big Time' Failure With Merck In Melanoma Taints Others Investor's Business Daily
03:59PM  How a Biotech Bummer Sent Nektar Therapeutics Stock South Today Motley Fool
03:44PM  Incyte-Merck trial fails in blow to cancer immunotherapy, but researchers remain hopeful CNBC
03:14PM  NewLink will review clinical programs after Merck, Incyte trial failure MarketWatch
01:54PM  Why Incyte and NewLink Genetics Crashed Today Motley Fool
12:41PM  [$$] Incyte Shares Fall After Cancer Drug Fails in Trial With Merck's Keytruda The Wall Street Journal
11:19AM  Incyte stock plummets following disappointing clinical study results American City Business Journals
11:09AM  Biotech Loses Key Bet to Reignite Growth as Incyte Trial Fails Bloomberg
09:30AM  Stocks to Watch: Incyte, JPMorgan, Boeing, WageWorks The Wall Street Journal
09:14AM  NewLink Genetics shares plummet 39% after Merck, Incyte trial failure MarketWatch
08:04AM  Incyte's stock plunges, Merck shares fall after disappointing study results of melanoma treatment MarketWatch
08:03AM  [$$] Incyte slumps 19% after combo therapy fails late-stage test Financial Times
07:44AM  Incyte's combo therapy for skin cancer fails in late-stage study Reuters
07:30AM  Incyte and Merck Provide Update on Phase 3 Study of Epacadostat in Combination with KEYTRUDA® (pembrolizumab) in Patients with Unresectable or Metastatic Melanoma Business Wire
Apr-05-18 06:00AM  4 Biotechs Ready for Big Rebounds Investopedia
Apr-02-18 06:33AM  Are Short-Sellers Right About Geron Corporation? Motley Fool
Mar-30-18 02:12PM  10 Deceptively Bad Stocks to Sell Before Youre Pranked InvestorPlace
Mar-29-18 08:45AM  Incyte Could Have a Problem (or 2!) on Its Hands Motley Fool
08:20AM  Todays Research Reports on Trending Tickers: Idera Pharmaceuticals and Incyte ACCESSWIRE
Mar-28-18 06:04AM  3 Biotechs That Could Get Big Boosts in April Motley Fool
Mar-27-18 07:00AM  Free Post Earnings Research Report: Incytes Quarterly Sales 36% Surged ACCESSWIRE
Mar-19-18 04:19AM  Incyte (INCY) Up 5.2% Since Earnings Report: Can It Continue? Zacks
Mar-18-18 08:47AM  Is Geron Corporation's Stock Set to Sail or Sink? Motley Fool
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. The company's clinical stage products include ruxolitinib, a drug that is in pivotal Phase II clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II clinical trial for the treatment of essential thrombocythemia, as well as Phase III clinical trials for steroid-refractory acute and chronic GVHDs. In addition, it is developing itacitinib that is in Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC), as well as Phase III clinical trial for naive acute GVHD; epacadostat that is in Phase III clinical trails for the treatment of melanoma, renal, bladder, head and neck, non-small cell lung cancers; MGA012 that is in Phase I clinical trial for solid tumors; INCB50465, which is in Phase II clinical trials for the treatment of diffuse large b-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma; and INCB54828 that is in Phase II clinical trials for the bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome. The company markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer; and MacroGenics, Inc. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BROOKE PAUL ADirectorJun 04Option Exercise2.8020,00056,000217,859Jun 06 04:33 PM
BAKER BROS. ADVISORS LPDirectorMay 02Option Exercise9.9260,000595,20029,267,937May 03 04:19 PM
Hoppenot HerveChairman / CEOMay 02Buy60.9415,000914,100276,690May 03 05:05 PM
SWAIN PAULA JEVP, Human ResourcesApr 30Option Exercise17.7980,0001,423,200107,267May 02 05:04 PM
SWAIN PAULA JEVP, Human ResourcesApr 30Sale62.4380,0004,994,40033,367May 02 05:04 PM
BROOKE PAUL ADirectorApr 05Option Exercise9.9220,000198,400217,859Apr 09 05:01 PM
GRYSKA DAVID WExecutive Vice President, CFOFeb 21Sale85.561,952167,01310,970Feb 22 04:46 PM
Huber Reid MEVP, Chief Scientific OfficerFeb 21Sale85.551,958167,50735,183Feb 22 04:23 PM
GRYSKA DAVID WExecutive Vice President, CFOJan 05Option Exercise83.836,760566,69120,752Jan 09 04:09 PM
GRYSKA DAVID WExecutive Vice President, CFOJan 05Sale98.876,760668,36113,992Jan 09 04:09 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJan 02Option Exercise72.865,000364,30013,676Jan 03 04:32 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJan 02Sale97.265,000486,3008,676Jan 03 04:32 PM
Huber Reid MEVP, Chief Scientific OfficerDec 01Sale98.0169668,21538,205Dec 05 04:01 PM
FRIEDMAN PAUL ADirectorNov 16Sale105.2428,5073,000,077269,011Nov 20 04:25 PM
GRYSKA DAVID WExecutive Vice President, CFONov 02Sale105.633,915413,54113,992Nov 03 04:01 PM
Hoppenot HerveChairman / CEOSep 18Sale119.4570,5028,421,464299,004Sep 20 04:28 PM
Flannelly Barry PEVP & General Manager USSep 14Sale124.2571488,71514,782Sep 15 04:11 PM
BAKER BROS. ADVISORS LPDirectorSep 08Buy132.00100,00013,200,00029,247,347Sep 08 05:06 PM
Trower PaulPrincipal Accounting OfficerSep 05Option Exercise17.793,00053,37014,853Sep 07 04:04 PM
Trower PaulPrincipal Accounting OfficerSep 05Sale138.413,000415,23011,853Sep 07 04:04 PM
Siegel Eric H.EVP, General CounselSep 01Option Exercise64.551,820117,48123,553Sep 05 04:27 PM
Siegel Eric H.EVP, General CounselSep 01Sale137.401,820250,06821,733Sep 05 04:27 PM
SWAIN PAULA JEVP, Human ResourcesAug 31Option Exercise17.7920,000355,80055,067Sep 05 04:22 PM
SWAIN PAULA JEVP, Human ResourcesAug 31Sale140.0020,0002,800,00035,067Sep 05 04:22 PM
Stein Steven HEVP & Chief Medical OfficerAug 29Option Exercise89.522,111188,97420,276Aug 31 04:13 PM
Stein Steven HEVP & Chief Medical OfficerAug 29Sale125.002,111263,87518,165Aug 31 04:13 PM
Trower PaulPrincipal Accounting OfficerAug 04Option Exercise17.793,00053,37014,853Aug 07 04:33 PM
Trower PaulPrincipal Accounting OfficerAug 04Sale125.253,000375,75011,853Aug 07 04:33 PM
Siegel Eric H.EVP, General CounselAug 01Option Exercise64.551,820117,48123,553Aug 03 04:54 PM
Siegel Eric H.EVP, General CounselAug 01Sale132.921,820241,91421,733Aug 03 04:54 PM
Stein Steven HEVP & Chief Medical OfficerJul 20Option Exercise85.686,485555,64124,650Jul 21 04:01 PM
Stein Steven HEVP & Chief Medical OfficerJul 20Sale131.096,485850,11918,165Jul 21 04:01 PM
Trower PaulPrincipal Accounting OfficerJul 05Option Exercise17.793,00053,37015,148Jul 07 05:02 PM
Trower PaulPrincipal Accounting OfficerJul 05Sale126.183,000378,54012,148Jul 07 05:02 PM
Siegel Eric H.EVP, General CounselJul 03Option Exercise64.551,820117,48120,036Jul 05 06:20 PM
Siegel Eric H.EVP, General CounselJul 03Sale126.201,820229,68418,216Jul 05 06:20 PM
GRYSKA DAVID WExecutive Vice President, CFOJun 30Option Exercise73.2159943,85319,614Jul 05 04:12 PM
GRYSKA DAVID WExecutive Vice President, CFOJun 30Sale129.7459977,71419,015Jul 05 04:12 PM